1. Combination with third‐generation bisphosphonate (YM529) and interferon‐alpha can inhibit the progression of established bone renal cell carcinoma. Issue 8 (14th July 2015) Authors: Kurabayashi, Atsushi; Inoue, Keiji; Fukuhara, Hideo; Karashima, Takashi; Fukata, Satoshi; Kawada, Chiaki; Shuin, Taro; Furihata, Mutsuo Journal: Cancer science Issue: Volume 106:Issue 8(2015:Aug.) Page Start: 1092 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Sarcopenia and the rate of change of the neutrophil/lymphocyte ratio as predictors of pembrolizumab efficacy in advanced urothelial carcinoma. Issue 5 (21st February 2022) Authors: Fukata, Satoshi; Mizutani, Keisuke; Yamamoto, Shinkuro; Kuno, Takahira; Fukuhara, Hideo; Ashida, Shingo; Karashima, Takashi; Inoue, Keiji Journal: Anti-cancer drugs Issue: Volume 33:Issue 5(2022) Page Start: 459 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Synchronous bilateral renal cell carcinomas with differing histologies. Issue 5 (28th June 2020) Authors: Shigehisa, Ryu; Karashima, Takashi; Kobayashi, Shu; Atagi, Kaya; Takemori, Daigo; Fukuhara, Hideo; Fukata, Satoshi; Murakami, Ichiro; Kuroda, Naoto; Inoue, Keiji Journal: IJU case reports Issue: Volume 3:Issue 5(2020) Page Start: 196 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗